PenRad Announces PenAlert

A New Paradigm In Diagnostic Imaging Reports In Patient's Language And Terminology

As various regulations evolve and malpractice rates increase, imaging providers need to take a proactive approach to notify patients directly of any significant abnormality or normal result. Pennsylvania (PA112) already has set a precedent, adding burden and liability concerns for radiologists and referring physicians.

PenRad, the Radiologists preferred mammography and LDCT reporting and tracking system, has created PenAlert in direct response by expanding the footprint to all diagnostic imaging. PenAlert automates patient notification with zero change to Radiologist workflow, while aiding in practice liability management. This enhances patient satisfaction, tracking patients and findings to resolution, and assists the referring physician with direct patient result notification. Currently, PenRad’s technology provides these benefits to more than 10,000,000 exams per year, in mammography alone.  PenAlert represents a move to provide these benefits to all diagnostic imaging and millions of additional exams.

PenAlert uses machine learning intelligence to extract key findings from the radiologist’s narrative report and catalogs the exam and findings. The patient exam letter describes findings and concerns, or normal results can be communicated as well, all in patient terminology. This automation inserts referring physician contact info, sub-specialty care specialists (if applicable), future recommended imaging, and more. All this detail is in the patient’s preferred language, with automated delivery via; email, mail, an existing Portal or our PenXpress patient portal.

Other features include recall letters, management reports, analytics for findings and outcomes. PenAlert facilitates compliance with key CMS quality payment program requirements and increases the opportunity to report compliance and best practices with Medicare’s Merit-based Incentive Payment System (MIPS).

SourcePenRad

Hot this week

Cartessa Aesthetics Partners with Classys to Bring EVERESSE to the U.S. Market

Classys, which is listed on the KOSDAQ, is one of South Korea's most distinguished aesthetic technology manufacturers, with devices distributed in 80+ markets globally. This partnership marks Classys's official entry into the American marketplace, with Cartessa Aesthetics as the exclusive distributor for EVERESSE, launched under the Volnewmer brand in current global markets.

Stryker Launches Next-Generation of SurgiCount+

Now integrated with Stryker's Triton technology, SurgiCount+ addresses two key challenges: retained surgical sponges and blood loss assessment. Integrating these previously separate digital solutions provides the added benefit of a more efficient, streamlined workflow for hospitals notes Stryker.

Nevro Receives CE Mark In Europe for It’s HFX iQ™ Spinal Cord Stimulation System

Nevro notes HFX iQ is the first and only SCS system with artificial intelligence (AI) technology that combines high-frequency (10 kHz) therapy built on landmark evidence that uses ongoing cloud data insights to deliver personalized pain relief

Recor Medical Reports: CMS Grants Distinct TPT Device Code and Category to Recor Medical for Ultrasound Renal Denervation

The approval of TPT offers incremental reimbursement payments for outpatient procedures performed with ultrasound renal denervation for Medicare fee-for-service beneficiaries. It becomes effective January 1, 2025, and is expected to remain effective for up to three years notes Recor Medical.

Jupiter Endovascular Reports | 1st U.S. Patient Treated with Jupiter Shape-shifting Thrombectomy Device

“Navigation challenges during endovascular procedures are often underappreciated and have led to under-adoption of life-saving procedures, such as pulmonary embolectomy. We have purpose-built our Endoportal Control technology to solve these issues and make important endovascular procedures accessible to more clinicians and their patients who can benefit from them,” said Carl J. St. Bernard, Jupiter Endovascular CEO. “This first case in the U.S. could not have gone better, and appears to validate the safety and performance we are seeing in our currently-enrolling European SPIRARE I study.”